JZUS - Journal of Zhejiang University SCIENCE

Journal of Zhejiang University SCIENCE B 2021 Vol.22 No.6 P.512-520

http://doi.org/10.1631/jzus.B2000555

Serum macrophage migration inhibitory factor as a potential biomarker to evaluate therapeutic response in patients with allergic asthma: an exploratory study

Author(s): Huiyuan ZHU, Shaochun YAN, Jingshuo WU, Zhong ZHANG, Xiaolin LI, Zheng LIU, Xing MA, Lina ZHOU, Lin ZHANG, Mingming FENG, Yiwei GENG, Aixin ZHANG, Sabina JANCIAUSKIENE, Aiguo XU
Affiliation(s): Department of Pulmonary and Critical Care Medicine, Zhengzhou Second People�s Hospital, Zhengzhou Affiliated Hospital of Jinan University, Zhengzhou 450006, China; more
Corresponding email(s): aiguoxu@zzu.edu.cn
Key Words: Macrophage migration inhibitory factor (MIF), Allergic asthma, Eosinophilic inflammation, Fractional exhaled nitric oxide, Immunoglobulin E (IgE)

Share this article to： More <<< Previous Article \|

Abstract: BackgroundPrevious studies have shown that macrophage migration inhibitory factor (MIF) is involved in the pathogenesis of asthma. This study aimed to investigate whether serum MIF reflects a therapeutic response in allergic asthma.
MethodsWe enrolled 30 asthmatic patients with mild-to-moderate exacerbations and 20 healthy controls, analyzing the parameter levels of serum MIF, serum total immunoglobulin E (tIgE), peripheral blood eosinophil percentage (EOS%), and fractional exhaled nitric oxide (FeNO). Lung function indices were used to identify disease severity and therapeutic response.
ResultsOur study showed that all measured parameters in patients were at higher levels than those of controls. After one week of treatment, most parameter levels decreased significantly except for serum tIgE. Furthermore, we found that serum MIF positively correlated with EOS% as well as FeNO, but negatively correlated with lung function indices. Receiver operator characteristic (ROC) curve analysis indicated that among the parameters, serum MIF exhibited a higher capacity to evaluate therapeutic response. The area under the curve (AUC) of MIF was 0.931, with a sensitivity of 0.967 and a specificity of 0.800.
ConclusionsOur results suggested that serum MIF may serve as a potential biomarker for evaluating therapeutic response in allergic asthma with mild-to-moderate exacerbations.

血清巨噬细胞移动抑制因子作为评估过敏性哮喘患者治疗反应的潜在标志物：一项探索性研究

目的：探讨血清巨噬细胞移动抑制因子在过敏性哮喘治疗反应评估中的应用价值。
创新点：采用血清巨噬细胞移动抑制因子评估过敏性哮喘的治疗反应。
方法：我们纳入了过敏性哮喘轻中度急性发作患者30例，并以20例健康人为对照，分别检测和分析了治疗前后患者以及健康人的血清巨噬细胞移动抑制因子、总免疫球蛋白E（总IgE）、外周血嗜酸性粒细胞百分数和呼出气一氧化氮等指标，同时进行肺功能检查以监测患者的治疗反应。
结论：血清巨噬细胞移动抑制因子作为一种潜在的生物标志物，可用于评估过敏性哮喘轻中度急性发作患者的治疗反应。

关键词：巨噬细胞移动抑制因子；过敏性哮喘；嗜酸性粒细胞炎症；呼出气一氧化氮；免疫球蛋白E（IgE）

Reference

[1]AgrawalDK, ShaoZF, 2010. Pathogenesis of allergic airway inflammation. Curr Allergy Asthma Rep, 10(1):39-48.

[2]Al-AbedY, VanPattenS, 2011. MIF as a disease target: ISO-1 as a proof-of-concept therapeutic. Future Med Chem, 3(1):45-63.

[3]AmanoT, NishihiraJ, MikiI, 2007. Blockade of macrophage migration inhibitory factor (MIF) prevents the antigen-induced response in a murine model of allergic airway inflammation. Inflamm Res, 56(1):24-31.

[4]ATS/ERS (American Thoracic Society, European Respiratory Society), 2005. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med, 171(8):912-930.

[5]Bar-YishayE, AmiravI, GoldbergS, 2003. Comparison of maximal midexpiratory flow rate and forced expiratory flow at 50% of vital capacity in children. Chest, 123(3):731-735.

[6]BernhagenJ, CalandraT, MitchellRA, et al., 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature, 365(6448):756-759.

[7]BloomBR, BennettB, 1966. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science, 153(3731):80-82.

[8]BozzaMT, LintomenL, KitokoJZ, et al., 2020. The role of MIF on eosinophil biology and eosinophilic inflammation. Clin Rev Allergy Immunol, 58(1):15-24.

[9]CaiC, YangJ, HuSP, et al., 2007. Relationship between urinary cysteinyl leukotriene E₄ levels and clinical response to antileukotriene treatment in patients with asthma. Lung, 185(2):105-112.

[10]CalandraT, RogerT, 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol, 3(10):791-800.

[11]CalandraT, EchtenacherB, le RoyD, et al., 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med, 6(2):164-170.

[12]ChenPF, LuoYL, WangW, et al., 2010. ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma. Mol Med, 16(9-10):400-408.

[13]ChungKF, WenzelSE, BrozekJL, et al., 2014. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 43(2):343-373.

[14]DasR, MossJE, RobinsonE, et al., 2011. Role of macrophage migration inhibitory factor in the Th2 immune response to epicutaneous sensitization. J Clin Immunol, 31(4):666-680.

[15]DavidJR, 1966. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA, 56(1):72-77.

[16]DweikRA, BoggsPB, ErzurumSC, et al., 2011. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med, 184(5):602-615.

[17]El-AdlyTZ, KamalS, SelimH, et al., 2016. Association of macrophage migration inhibitory factor promoter polymorphism -173G/C with susceptibility to childhood asthma. Cent Eur J Immunol, 41(3):268-272.

[18]FitzpatrickAM, GastonBM, ErzurumSC, et al., 2006. Features of severe asthma in school-age children: atopy and increased exhaled nitric oxide. J Allergy Clin Immunol, 118(6):1218-1225.

[19]GINA (Global Initiative for Asthma), 2019. Global strategy for asthma management and prevention, 2019. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

[20]KobayashiM, NasuharaY, KamachiA, et al., 2006. Role of macrophage migration inhibitory factor in ovalbumin-induced airway inflammation in rats. Eur Respir J, 27(4):726-734.

[21]LaiKN, LeungJC, MetzCN, et al., 2003. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol, 199(4):496-508.

[22]LangT, FooteA, LeeJPW, et al., 2015. MIF: implications in the pathoetiology of systemic lupus erythematosus. Front Immunol, 6:577.

[23]MillerMR, HankinsonJ, BrusascoV, et al., 2005. Standardisation of spirometry. Eur Respir J, 26(2):319-338.

[24]MizueY, GhaniS, LengL, et al., 2005. Role for macrophage migration inhibitory factor in asthma. Proc Natl Acad Sci USA, 102(40):14410-14415.

[25]NishihiraJ, IshibashiT, FukushimaT, et al., 2003. Macrophage migration inhibitory factor (MIF): its potential role in tumor growth and tumor-associated angiogenesis. Ann N Y Acad Sci, 995(1):171-182.

[26]PellegrinoR, ViegiG, BrusascoV, et al., 2005. Interpretative strategies for lung function tests. Eur Respir J, 26(5):948-968.

[27]RaziE, MoosaviGA, 2010. Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma. J Bras Pneumol, 36(1):23-28.

[28]RossiAG, HaslettC, HiraniN, et al., 1998. Human circulating eosinophils secrete macrophage migration inhibitory factor (MIF). Potential role in asthma. J Clin Invest, 101(12):2869-2874.

[29]TanYQ, CaoLF, ShenJ, et al., 2012. Climatic factors correlate with innate immune response in children with Dermatophagoides farinae-induced allergic asthma. J Int Med Res, 40(2):740-747.

[30]ToT, StanojevicS, MooresG, et al., 2012. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12:204.

[31]WangB, HuangXZ, WoltersPJ, et al., 2006. Cutting edge: deficiency of macrophage migration inhibitory factor impairs murine airway allergic responses. J Immunol, 177(9):5779-5784.

[32]WuJ, FuS, RenX, et al., 2009. Association of MIF promoter polymorphisms with childhood asthma in a northeastern Chinese population. Tissue Antigens, 73(4):302-306.

[33]YamaguchiE, NishihiraJ, ShimizuT, et al., 2000. Macrophage migration inhibitory factor (MIF) in bronchial asthma. Clin Exp Allergy, 30(9):1244-1249.

[34]ZerneckeA, BernhagenJ, WeberC, 2008. Macrophage migration inhibitory factor in cardiovascular disease. Circulation, 117(12):1594-1602.

[35]ZhangXY, SimpsonJL, PowellH, et al., 2014. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy, 44(9):1137-1145.

[36]ZhaoST, WangCZ, 2018. Regulatory T cells and asthma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(9):663-673.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Similar articles

- Go to

血清巨噬细胞移动抑制因子作为评估过敏性哮喘患者治疗反应的潜在标志物：一项探索性研究

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference